Correcting and replacing -- pds biotech announces release of interim data for pds0101 in nci-led phase 2 clinical study in oral presentation at asco 2021 annual meeting

Tumor reduction was observed in 83% (5 of 6) of hpv16-positive relapsed or refractory checkpoint inhibitor naÏve advanced cancer patients and 58% (7 of 12) of hpv16-positive relapsed or refractory advanced cancer patients who have also failed checkpoint inhibitor therapy tumor reduction was observed in 83% (5 of 6) of hpv16-positive relapsed or refractory checkpoint inhibitor naÏve advanced cancer patients and 58% (7 of 12) of hpv16-positive relapsed or refractory advanced cancer patients who have also failed checkpoint inhibitor therapy
PDSB Ratings Summary
PDSB Quant Ranking